Nebra Eye Oint 5G

140

Description

Indications

Nebra Eye Oint 5G is primarily indicated in conditions like Bacterial infections, Biliary tract infections, Chronic pulmonary pseudomonas aeruginosa infection in cystic fibrosis patients, Cystic fibrosis, Endocarditis, Eye infections, Gram +ve (some) and gram -ve (many) infections, Heart failure, Iron deficiency anaemia, NSAID-associated ulceration, Oliguria due to renal failure, Pneumonia in hospital patients, Prohylaxis of stress ulceration, Respiratory tract infections, Septicaemia, Supraventricular arrhythmias (particularly atrial fibrillation), Symptoms associated with carcinoid tumours, Trauma, Ulcerative colitis and crohn’s disease, Urinary tract infection, UTI.

Contraindication

Nebra Eye Oint 5G is contraindicated in conditions like Hypersensitivity.

Side Effects

The severe or irreversible adverse effects of Nebra Eye Oint 5G, which give rise to further complications include Ototoxicity, Elevation in serum creatinine, Neuromuscular blockage. Nebra Eye Oint 5G produces potentially life-threatening effects which include Nephrotoxicity, Dehydration, Proteinuria, Oliguria, Hyperuricemia. which are responsible for the discontinuation of Nebra Eye Oint 5G therapy.The symptomatic adverse reactions produced by Nebra Eye Oint 5G are more or less tolerable and if they become severe, they can be treated symptomatically, these include Skin reactions, Maculopapular rash, Urticaria, Local pain, Phlebitis.

Warnings

Nebra Eye Oint 5G should be used with caution in patients with history of kidney diseases, vertigo, hearing loss, myasthenia gravis, parkinsonisms. It should be used with caution in patients who are sensitive to aminoglycosides. Perform monthly blood counts test for atleast 4 months. Keep patients well hydrated to prevent chemical irritation or nephrotoxic reactions. Take appropriate measures in case of secondary infections.

Reviews

There are no reviews yet.

Be the first to review “Nebra Eye Oint 5G”

Your email address will not be published. Required fields are marked *